Skip to main content
Erschienen in: Medical Oncology 3/2014

01.03.2014 | Original Paper

Association between EZH2 polymorphisms and colorectal cancer risk in Han Chinese population

verfasst von: Jian Wang, Zhen-Bin Ma, Kun Li, Guang-Hong Guo

Erschienen in: Medical Oncology | Ausgabe 3/2014

Einloggen, um Zugang zu erhalten

Abstract

The aim of this study is to investigate the associations between EZH2 gene polymorphisms and colorectal cancer (CRC) risk. We undertook a case–control study to analyze three EZH2 polymorphisms (148505302C>T, 2110+6A>C and 626-394T>C) in an Han Chinese population, by extraction of genomic DNA from the peripheral blood of 512 patients with CRC and 546 control participants, and performed EZH2 genotyping using DNA sequencing. The obtained results indicated that overall, no statistically significant association was observed in 2,110+6A>C. Nevertheless, 148505302C>T genotype demonstrated a protective effect in CRCs (P = 0.014; odds ratio (OR) 0.777, CI 95 %:0.647–0.933). Furthermore, 148505302 T allele CRC was more significantly common in patients with tumor size of <4 cm than C allele CRC and in cases of good differentiation and lower advanced pathological stage. However, 626-394T>C genotype was at increased risk of CRCs (P < 0.001; odds ratio (OR) 1.457, CI 95 %:1.160–1.829). Moreover, 626-394C/C genotype CRCs were more significantly common in patients with tumor size of >4 cm than T allele CRC and in cases of poor differentiation and lower advanced pathological stage. In conclusion, polymorphism in 626-394T>C was observed to be associated with susceptibility of CRC. However, 148505302C>T polymorphism indicated to play a protective role in susceptibility to CRC. Nevertheless, further investigation with a larger sample size is needed to support our results.
Literatur
3.
Zurück zum Zitat Tannapfel A, Neid M, Aust D, Baretton G. The origins of colorectal carcinoma: specific nomenclature for different pathways and precursor lesions. Deutsches Arzteblatt Int. 2010;107(43):760–6. doi:10.3238/arztebl 2010.0760. Tannapfel A, Neid M, Aust D, Baretton G. The origins of colorectal carcinoma: specific nomenclature for different pathways and precursor lesions. Deutsches Arzteblatt Int. 2010;107(43):760–6. doi:10.​3238/​arztebl 2010.0760.
5.
Zurück zum Zitat Hu JJ, Mohrenweiser HW, Bell DA, Leadon SA, Miller MS. Symposium overview: genetic polymorphisms in DNA repair and cancer risk. Toxicol Appl Pharmacol. 2002;185(1):64–73.PubMedCrossRef Hu JJ, Mohrenweiser HW, Bell DA, Leadon SA, Miller MS. Symposium overview: genetic polymorphisms in DNA repair and cancer risk. Toxicol Appl Pharmacol. 2002;185(1):64–73.PubMedCrossRef
6.
Zurück zum Zitat Aiello M, Vella N, Cannavo C, Scalisi A, Spandidos DA, Toffoli G, et al. Role of genetic polymorphisms and mutations in colorectal cancer therapy (Review). Mol Med Rep. 2011;4(2):203–8. doi:10.3892/mmr.2010.408.PubMed Aiello M, Vella N, Cannavo C, Scalisi A, Spandidos DA, Toffoli G, et al. Role of genetic polymorphisms and mutations in colorectal cancer therapy (Review). Mol Med Rep. 2011;4(2):203–8. doi:10.​3892/​mmr.​2010.​408.PubMed
9.
Zurück zum Zitat Tonini T, D’Andrilli G, Fucito A, Gaspa L, Bagella L. Importance of Ezh2 polycomb protein in tumorigenesis process interfering with the pathway of growth suppressive key elements. J Cell Physiol. 2008;214(2):295–300. doi:10.1002/jcp.21241.PubMedCrossRef Tonini T, D’Andrilli G, Fucito A, Gaspa L, Bagella L. Importance of Ezh2 polycomb protein in tumorigenesis process interfering with the pathway of growth suppressive key elements. J Cell Physiol. 2008;214(2):295–300. doi:10.​1002/​jcp.​21241.PubMedCrossRef
10.
Zurück zum Zitat Cardoso C, Mignon C, Hetet G, Grandchamps B, Fontes M, Colleaux L. The human EZH2 gene: genomic organisation and revised mapping in 7q35 within the critical region for malignant myeloid disorders. Eur J Human Genet. 2000;8(3):174–80. doi:10.1038/sj.ejhg.5200439.CrossRef Cardoso C, Mignon C, Hetet G, Grandchamps B, Fontes M, Colleaux L. The human EZH2 gene: genomic organisation and revised mapping in 7q35 within the critical region for malignant myeloid disorders. Eur J Human Genet. 2000;8(3):174–80. doi:10.​1038/​sj.​ejhg.​5200439.CrossRef
11.
Zurück zum Zitat van Kemenade FJ, Raaphorst FM, Blokzijl T, Fieret E, Hamer KM, Satijn DP, et al. Coexpression of BMI-1 and EZH2 polycomb-group proteins is associated with cycling cells and degree of malignancy in B-cell non-Hodgkin lymphoma. Blood. 2001;97(12):3896–901.PubMedCrossRef van Kemenade FJ, Raaphorst FM, Blokzijl T, Fieret E, Hamer KM, Satijn DP, et al. Coexpression of BMI-1 and EZH2 polycomb-group proteins is associated with cycling cells and degree of malignancy in B-cell non-Hodgkin lymphoma. Blood. 2001;97(12):3896–901.PubMedCrossRef
13.
Zurück zum Zitat Mimori K, Ogawa K, Okamoto M, Sudo T, Inoue H, Mori M. Clinical significance of enhancer of zeste homolog 2 expression in colorectal cancer cases. Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol. 2005;31(4):376–80. doi:10.1016/j.ejso.2004.11.001. Mimori K, Ogawa K, Okamoto M, Sudo T, Inoue H, Mori M. Clinical significance of enhancer of zeste homolog 2 expression in colorectal cancer cases. Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol. 2005;31(4):376–80. doi:10.​1016/​j.​ejso.​2004.​11.​001.
14.
Zurück zum Zitat Collett K, Eide GE, Arnes J, Stefansson IM, Eide J, Braaten A, et al. Expression of enhancer of zeste homologue 2 is significantly associated with increased tumor cell proliferation and is a marker of aggressive breast cancer. Clin Cancer Res. 2006;12(4):1168–74. doi:10.1158/1078-0432.CCR-05-1533.PubMedCrossRef Collett K, Eide GE, Arnes J, Stefansson IM, Eide J, Braaten A, et al. Expression of enhancer of zeste homologue 2 is significantly associated with increased tumor cell proliferation and is a marker of aggressive breast cancer. Clin Cancer Res. 2006;12(4):1168–74. doi:10.​1158/​1078-0432.​CCR-05-1533.PubMedCrossRef
15.
Zurück zum Zitat Bachmann IM, Halvorsen OJ, Collett K, Stefansson IM, Straume O, Haukaas SA, et al. EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J Clin Oncol. 2006;24(2):268–73. doi:10.1200/JCO.2005.01.5180.PubMedCrossRef Bachmann IM, Halvorsen OJ, Collett K, Stefansson IM, Straume O, Haukaas SA, et al. EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J Clin Oncol. 2006;24(2):268–73. doi:10.​1200/​JCO.​2005.​01.​5180.PubMedCrossRef
17.
Zurück zum Zitat Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG, et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature. 2002;419(6907):624–9. doi:10.1038/nature01075.PubMedCrossRef Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG, et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature. 2002;419(6907):624–9. doi:10.​1038/​nature01075.PubMedCrossRef
19.
Zurück zum Zitat Edge SB. American Joint Committee on Cancer. AJCC cancer staging manual. 7th ed. New York: Springer; 2010. Edge SB. American Joint Committee on Cancer. AJCC cancer staging manual. 7th ed. New York: Springer; 2010.
20.
Zurück zum Zitat Nazir M, Kayani MR, Malik FA, Masood N, Kayani MA. Lack of germ line changes in KISS1 and KAI1 genes in sporadic head and neck cancer patients of Pakistani origin. Asian Pac J Cancer Prev. 2011;12(10):2767–71.PubMed Nazir M, Kayani MR, Malik FA, Masood N, Kayani MA. Lack of germ line changes in KISS1 and KAI1 genes in sporadic head and neck cancer patients of Pakistani origin. Asian Pac J Cancer Prev. 2011;12(10):2767–71.PubMed
22.
Zurück zum Zitat van Kemenade FJ, Raaphorst FM, Blokzijl T, Fieret E, Hamer KM, Satijn DP, et al. Coexpression of BMI-1 and EZH2 polycomb-group proteins is associated with cycling cells and degree of malignancy in B-cell non-Hodgkin lymphoma. Blood. 2001;97(12):3896–901.PubMedCrossRef van Kemenade FJ, Raaphorst FM, Blokzijl T, Fieret E, Hamer KM, Satijn DP, et al. Coexpression of BMI-1 and EZH2 polycomb-group proteins is associated with cycling cells and degree of malignancy in B-cell non-Hodgkin lymphoma. Blood. 2001;97(12):3896–901.PubMedCrossRef
23.
Zurück zum Zitat Matsukawa Y, Semba S, Kato H, Ito A, Yanagihara K, Yokozaki H. Expression of the enhancer of zeste homolog 2 is correlated with poor prognosis in human gastric cancer. Cancer Sci. 2006;97(6):484–91.PubMedCrossRef Matsukawa Y, Semba S, Kato H, Ito A, Yanagihara K, Yokozaki H. Expression of the enhancer of zeste homolog 2 is correlated with poor prognosis in human gastric cancer. Cancer Sci. 2006;97(6):484–91.PubMedCrossRef
24.
Zurück zum Zitat Bachmann IM, Halvorsen OJ, Collett K, Stefansson IM, Straume O, Haukaas SA, et al. EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J Clin Oncol. 2006;24(2):268–73.PubMedCrossRef Bachmann IM, Halvorsen OJ, Collett K, Stefansson IM, Straume O, Haukaas SA, et al. EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J Clin Oncol. 2006;24(2):268–73.PubMedCrossRef
25.
Zurück zum Zitat Raman JD, Mongan NP, Tickoo SK, Boorjian SA, Scherr DS, Gudas LJ. Increased expression of the polycomb group gene, EZH2, in transitional cell carcinoma of the bladder. Clin Cancer Res. 2005;11(24):8570–6.PubMedCrossRef Raman JD, Mongan NP, Tickoo SK, Boorjian SA, Scherr DS, Gudas LJ. Increased expression of the polycomb group gene, EZH2, in transitional cell carcinoma of the bladder. Clin Cancer Res. 2005;11(24):8570–6.PubMedCrossRef
26.
Zurück zum Zitat Crea F, Fornaro L, Paolicchi E, Masi G, Frumento P, Loupakis F, et al. An EZH2 polymorphism is associated with clinical outcome in metastatic colorectal cancer patients. Ann Oncol. 2012;23(5):1207–13.PubMedCrossRef Crea F, Fornaro L, Paolicchi E, Masi G, Frumento P, Loupakis F, et al. An EZH2 polymorphism is associated with clinical outcome in metastatic colorectal cancer patients. Ann Oncol. 2012;23(5):1207–13.PubMedCrossRef
28.
Zurück zum Zitat Shen Z, Chen L, Hao F, Wang G, Fan P, Liu Y. Intron-1 rs3761548 is related to the defective transcription of Foxp3 in psoriasis through abrogating E47/c-Myb binding. J Cell Mol Med. 2010;14(1–2):226–41.PubMedCrossRef Shen Z, Chen L, Hao F, Wang G, Fan P, Liu Y. Intron-1 rs3761548 is related to the defective transcription of Foxp3 in psoriasis through abrogating E47/c-Myb binding. J Cell Mol Med. 2010;14(1–2):226–41.PubMedCrossRef
29.
Zurück zum Zitat Zhang W, Winder T, Ning Y, Pohl A, Yang D, Kahn M, et al. A let-7 microRNA-binding site polymorphism in 3′-untranslated region of KRAS gene predicts response in wild-type KRAS patients with metastatic colorectal cancer treated with cetuximab monotherapy. Ann Oncol. 2011;22(1):104–9.PubMedCrossRef Zhang W, Winder T, Ning Y, Pohl A, Yang D, Kahn M, et al. A let-7 microRNA-binding site polymorphism in 3′-untranslated region of KRAS gene predicts response in wild-type KRAS patients with metastatic colorectal cancer treated with cetuximab monotherapy. Ann Oncol. 2011;22(1):104–9.PubMedCrossRef
30.
Zurück zum Zitat Lipkin SM, Chao EC, Moreno V, Rozek LS, Rennert H, Pinchev M, et al. Genetic variation in 3-hydroxy-3-methylglutaryl CoA reductase modifies the chemopreventive activity of statins for colorectal cancer. Cancer Prev Res (Phila). 2010;3(5):597–603. doi:10.1158/1940-6207.CAPR-10-0007.CrossRef Lipkin SM, Chao EC, Moreno V, Rozek LS, Rennert H, Pinchev M, et al. Genetic variation in 3-hydroxy-3-methylglutaryl CoA reductase modifies the chemopreventive activity of statins for colorectal cancer. Cancer Prev Res (Phila). 2010;3(5):597–603. doi:10.​1158/​1940-6207.​CAPR-10-0007.CrossRef
31.
Zurück zum Zitat Fornaro L, Crea F, Masi G, Paolicchi E, Loupakis F, Graziano F, et al. EZH2 polymorphism and benefit from bevacizumab in colorectal cancer: another piece to the puzzle. Ann Oncol. 2012;23(5):1370–1. doi:10.1093/annonc/mds031.PubMedCrossRef Fornaro L, Crea F, Masi G, Paolicchi E, Loupakis F, Graziano F, et al. EZH2 polymorphism and benefit from bevacizumab in colorectal cancer: another piece to the puzzle. Ann Oncol. 2012;23(5):1370–1. doi:10.​1093/​annonc/​mds031.PubMedCrossRef
Metadaten
Titel
Association between EZH2 polymorphisms and colorectal cancer risk in Han Chinese population
verfasst von
Jian Wang
Zhen-Bin Ma
Kun Li
Guang-Hong Guo
Publikationsdatum
01.03.2014
Verlag
Springer US
Erschienen in
Medical Oncology / Ausgabe 3/2014
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-014-0874-y

Weitere Artikel der Ausgabe 3/2014

Medical Oncology 3/2014 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.